- egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Boardon March 26, 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- #digitalhealth--egnite, Inc. Announces the Appointment of Vinod Thourani and Nicholas Amoroso to Its Medical Advisory Board
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Programon March 26, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announces that its flagship Tru Niagen® product portfolio is now third-party verified through the Alkemist Assured™ testing transparency program by Alkemist Labs, a leading third-party testing laboratory known for its rigorous herbal and dietary supplement analysis. As the number one NAD+ supplement company in the US†, Tru Niagen features NIAG
- A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directorson March 25, 2024
AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2Bio--A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors
- Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Dataon March 25, 2024
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has initiated an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for patients with familial chylomicronemia syndrome (FCS) who meet certain program eligibility criteria. Arrowhead will also present new final Phase 2 clinical data from the double-blind portion of the SHASTA-2 study of plozasiran in a late-breaking oral presentation at th
- Grindr Partners with Burnett Foundation Aotearoa to Offer Free At-Home HIV Test Kits to Grindr Users Throughout New Zealandon March 24, 2024
LOS ANGELES--(BUSINESS WIRE)--Grindr Inc. (NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnership with Burnett Foundation Aotearoa to offer free HIV self-test kits to Grindr users throughout New Zealand. The partnership is the latest step in Grindr’s expansion of its work to advance public health for the LGBTQ+ community, driven by Grindr for Equality, the company’s global social impact initiative. As of today, Grindr users in
- Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Businesson March 22, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that its Board of Directors has authorized management to evaluate a proposed separation of its consumer business. The Board and management will evaluate the proposed structure of the separation. Masimo expects that the separation will include its consumer audio and consumer health products, including the Stork baby monitor and the Freedom smart watch
- Axonics Stockholders Approve Merger Agreement with Boston Scientificon March 22, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics’ merger agreement with Boston Scientific Corporation (NYSE: BSX). According to preliminary voting results from the special meeting of stockholders held earlier today, a majority of the shares of Axonics’ common stock outstanding and entitled to vote at the special meeting voted in favor of adopting the merger agreement. Final voting results, as tabulated by an independ
- Dr. Gary K. Michelson and Alya Michelson Receive 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Annual Gathering for Cure Awardson March 22, 2024
LOS ANGELES--(BUSINESS WIRE)--Inventor and philanthropist Dr. Gary K. Michelson and his wife Alya Michelson received the 2024 Humanitarian Award at the World Brain Mapping Foundation’s 21st Gathering for Cure (GFC) Awards Gala at the Biltmore Hotel in Los Angeles. The Humanitarian Award is given to individuals who have contributed significantly to survival and quality of life of patients across the Globe. Previous recipients of the annual award include Dr. Anthony Fauci, Dr. Sanjay Gupta, and M
- Applied BioCode Announces Retirement of CEO Chris Bernardon March 21, 2024
SANTA FE SPRINGS, Calif.--(BUSINESS WIRE)--Applied BioCode announced today the retirement of Chris Bernard as Chief Executive Officer. Chris Bernard has served as CEO for the past two years and has been instrumental in guiding the company through a period of growth and innovation. During his tenure, Chris played a pivotal role in advancing Applied BioCode’s strategic initiatives and driving the company’s commitment to delivering cutting-edge solutions to the molecular diagnostics market. His le
- Axonics Provides Update on Inter Partes Review Proceedingson March 21, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued written decisions on two Medtronic patents that Axonics is contesting. The PTAB issued its decision with respect to Patent Nos. 8,626,314 (“the ‘314 patent”) and 8,036,756 (“the ‘756 patent”). Medtronic has asserted these patents, which expired in 2021 and 2022, against Axonics’ proprietary tined lead design. Today, the PT
- SetPoint Medical Accepted into FDA Total Product Life Cycle Advisory Program for Development of its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosison March 21, 2024
VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical accepted into FDA TAP Pilot for development of its neuroimmune modulation platform for the treatment of Multiple Sclerosis
- Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Dateon March 20, 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will hold a conference call to discuss the Company's 2nd quarter FY24 financial results on Wed, April 3, 2024, at 5pm EDT.
- DeciBio Forecasts the Spatial Biology Market, Growing at 21% p.a. to Reach $2.27B in 2029 - Market Report by DeciBio Consulting LLCon March 20, 2024
LOS ANGELES--(BUSINESS WIRE)-- #biomarkers--DeciBio Consulting LLC’s latest market report, “Spatial Biology Market Report, Second Edition: 2024-2029,” states that the global spatial biology market is predicted to reach $2.27B by 2029. The second edition of DeciBio’s spatial biology market report takes a comprehensive look at the global spatial biology products and services market landscape, summarizing both present and future (2024-2029) use. Informed by a combination of primary research, secondary research,
- Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Canceron March 20, 2024
LOS ANGELES--(BUSINESS WIRE)--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.
- Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Canceron March 20, 2024
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy. Agendia has been in partnership with Quantum Leap Healthcare Collaborative, the sponsors of the neoadjuvant biomarker-rich I-SPY 2 trial, since 2010. I-SPY 2 established a new benchmark f
- Masimo Named One of Fast Company’s Most Innovative Companies in North Americaon March 19, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Masimo has been named one of Fast Company's Most Innovative Companies in North America for 2024.
- Immunis Publishes Research Showing Secretomes Improve Metabolism and Muscle While Reducing Fat in Aged Modelson March 19, 2024
IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis Inc., a private biotechnology company developing novel secretome therapeutics for age-related diseases and immune dysfunction, announces the peer-reviewed publication of research by Immunis and the University of Utah’s Professor Micah Drummond. The study, published in Aging Cell, is entitled “Stem cell secretome-treatment improves whole-body metabolism, reduces adiposity and promotes skeletal muscle function in aged mice.” The research examines the effec
- Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024on March 19, 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)-- #digitalhealth--Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024
- Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshoton March 18, 2024
IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles. Dr. Peter Diamandis is the world-renown entrepreneur and mastermind behind Abundance360, which fosters collaboration between prominent figures in space, technology, education, venture capital and longevity research. In the past decade,
- AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for ALG-801on March 18, 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company dedicated to developing first-in-class and best-in-class therapeutics for treating muscle wasting, metabolic disorders, and neuromuscular diseases, is delighted to announce the successful completion of its Phase 1b multiple-ascending dose (MAD) clinical trial for ALG-801. ALG-801 is a novel, next-generation ligand trap, which selectively sequesters a subset of TGF-beta family, includ
- STAAR Surgical Celebrates Three Million Implantable Collamer® Lenseson March 18, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1 “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction as we celebrate our three million lens
- Podcast: European Space Agency Talks SpaceTech, Challenges and Opportunitieson March 14, 2024
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Podcast: European Space Agency Talks SpaceTech, Challenges and Opportunities
- LIBERTY Dental Plan Launches Innovations in Oral Health with Generative Artificial Intelligence (GenAI) Capabilities in Care Management and Enhancements to Its Benefits and Rewards for Utilization, Services, and Healthy Outcomes (B.R.U.S.H.®) Programon March 14, 2024
TUSTIN, Calif.--(BUSINESS WIRE)--LIBERTY Dental Plan, a leading benefits administrator founded in 2002 by dentists and health industry professionals which currently administers dental benefits in all 50 states, today announced the launch of two innovative advancements in the company’s case management platform and the company’s B.R.U.S.H. program. "We are thrilled to introduce our GenAI-based Care Management, LIBERTY’s new dedicated Care Management platform powered by careassistant.ai, developed
- Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summiton March 14, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that Matt Thompson, President and CEO, will present at the Life Science Intelligence (LSI) USA '24 Emerging Medtech Summit. Scheduled for March 20, 2024, at 10:55 am PT on Track 3, Thompson will offer insights into the company's innovative portfolio and its impact on vascular disease trea
- Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation Systemon March 14, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that the Axonics R20™ rechargeable sacral neuromodulation (SNM) system has received CE Mark approval. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once
- Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forumon March 13, 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be presenting at KeyBanc Capital Markets Virtual Investor Forum on March 20, 2024, at 4:30 p.m. EDT.
- SetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple Sclerosison March 13, 2024
VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the use of its novel neuroimmune modulation platform for people living with relapsing-remitting multiple sclerosis (RRMS). Breakthrough Device Designation will enable interactive communication and priority regulatory review with the FDA,
- Nature Made® Introduces Zero Sugar‡ Gummies to Help Even More Consumers Incorporate Vitamin & Supplement Solutions into Their Wellness Routineson March 12, 2024
WEST HILLS, Calif.--(BUSINESS WIRE)--Nature Made, the leading national vitamin and supplement broadline brand with over 50 years of delivering high-quality products backed by science, today announces the launch of Nature Made Zero Sugar‡ Gummies, a new product line formulated to deliver the support of current Nature Made Gummies without the sugar, to offer more enjoyable supplementation experiences that align with a wider variety of dietary preferences. "As demand for more personalized, sensory
- City of Hope to Present New Research at the American Association of Cancer Research (AACR) Annual Meeting 2024, Highlighting Promising Data on Prostate, Colorectal and Pancreatic Canceron March 12, 2024
LOS ANGELES--(BUSINESS WIRE)--Researchers with City of Hope®, one of the largest cancer research and treatment organizations in the United States, will present new findings at the AACR Annual Meeting, which will take place April 5 to 10 in San Diego. This year, City of Hope doctors and scientists will also present data during AACR’s Press Program and a clinical trials plenary session: Monday, April 8, 2024, at 8:30 a.m. Research by Ajay Goel, Ph.D., M.S., City of Hope professor and chair, Depar
- Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnosticson March 12, 2024
BREA, Calif. & TOKYO--(BUSINESS WIRE)-- #IVD--Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays. In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based
- Ambry Genetics Announces a Collaboration with Tempus to Advance Paired Germline and Somatic Testing Services for Medical Oncologistson March 12, 2024
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (Ambry), a leader in clinical diagnostic testing, and Tempus, a leader in artificial intelligence and precision medicine, announced today that they have entered into a strategic collaboration to offer best-in-class, comprehensive, germline and somatic testing services. As part of the agreement, Ambry is performing germline sequencing assays for Tempus, powered by Ambry’s CancerNext® and CancerNext-Expanded® assays. Utilizing next-generation s
- STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directorson March 12, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism and presbyopia, today announced the appointment of Arthur Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific for Boston Scientific, and Wei Jiang, retired Executive Vice President and President of Bayer Pharmaceuticals Region China & APAC, to its Board of Direct
- FIGS Announces Participation in the 36th Annual Roth Conferenceon March 11, 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the direct-to-consumer apparel and lifestyle brand dedicated to the healthcare community, today announced that Daniella Turenshine, Chief Financial Officer, is scheduled to participate in a fireside chat at the 36th Annual Roth Conference on Monday, March 18, 2024, at 1:00 p.m. ET. The audio portion of the fireside chat will be webcast live over the internet and can be accessed at https://ir.wearfigs.com. An online archive will be
- Sonendo Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Full Year 2024 Revenue Guidanceon March 11, 2024
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (OTCQX: SONX) (“Sonendo” or the “Company”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2023. Highlights Total revenue of $43.9 million for the full year 2023, representing growth of 5% over the full year 2022 As of December 31, 2023, the installed base was 1,134 units, representing growth of approximately 16% compared to December 31,
- Convergent Research Announces Major New Funding Commitment to Forest Neurotechon March 11, 2024
LOS ANGELES--(BUSINESS WIRE)--Initiative will transform neurotechnology with minimally invasive ultrasound.
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Canceron March 11, 2024
SAN DIEGO & LOS ANGELES--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics and City of Hope Announce Funding from CIRM to Advance CLD-101 (NeuroNova) in Ovarian Cancer
- Sonendo Announces Departure of Chief Financial Officeron March 8, 2024
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. (OTCQX: SONX) (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today announced that Michael P. Watts is stepping down from the position of Chief Financial Officer, effective March 15, 2024, to pursue new opportunities. Chris Guo, Sonendo’s Vice President Finance and Corporate Controller, has been appointed as Interim Chief Financial Officer. Mr. Guo brings extensive experience leading corporate account
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)on March 8, 2024
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 11,355 shares of Evolus and an aggregate of 82,730 restricted stock units (RSUs) of the company’s common stock to 8 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of
- Dermavant Presents New Data on Treatment of Patients with Skin of Color from ADORING 1 and 2 Phase 3 Pivotal Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meetingon March 8, 2024
LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Presents New Data on Patients with Skin of Color from ADORING 1 and 2 Trials of VTAMA® Cream, 1% in Atopic Dermatitis at AAD 2024
- Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimenson March 8, 2024
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia®, Inc., announced today it will share new data from the ongoing prospective, observational FLEX Trial (NCT03053193) in two poster presentations at the 41st Annual Miami Breast Cancer Conference (MBCC), taking place March 7 – 10th, 2024. The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.), investigates the association
- KARL STORZ Launches CollaboratOR 3D for Apple Vision Proon March 7, 2024
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pioneering MedTech company KARL STORZ is proud to announce the release of the CollaboratOR 3D app for Apple Vision Pro. Designed in concert with innovative software developer T1V, the CollaboratOR 3D app complements the functionality of the integrated operating room solution known as OR1. KARL STORZ has a longstanding commitment to training and educating healthcare professionals to help them take full advantage of emerging medical technologies. Working close
- Herbalife Welcomes Back Michael Levitt to Board of Directorson March 7, 2024
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, today announced the appointment of veteran finance executive, Michael Levitt, to its Board of Directors, effective March 1, 2024. Levitt previously served on the Company’s Board as the Lead Director from 2011 to 2014. Kevin Jones, who has served as a director since 2021, will step down from his role on the Board. “We are honored to welcome Michael back to our Board,” said Michael Johnson, Chairman a
- City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trialon March 7, 2024
LOS ANGELES--(BUSINESS WIRE)--A pioneering Phase 1 CAR T cell therapy trial for the treatment of glioblastoma at City of Hope, one of the largest cancer treatment and research organizations in the United States, demonstrates promising clinical activity against incurable brain tumors, according to research published today in Nature Medicine. The study, which is the largest reported trial to date of CAR T therapy for solid tumors, evaluated CAR T cells engineered to target the tumor-associated an
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Resultson March 6, 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Total net sales of $21.2 million, with $17.6 million from Tru Niagen®, up 1% and 9%, respectively, from the prior year quarter. Delivered strong gross margin of 61.0%, an increase of 380 basis points, compared to 57.2% from the prior year quarter. Achieved net income of $0.1 million, a $1.5 million improvement from a net los
- InBody Unveils Transformative New Leasing Program, Devices at IHRSAon March 6, 2024
CERRITOS, Calif.--(BUSINESS WIRE)--At the IHRSA conference in Los Angeles, medical device pioneer InBody will discuss the biggest financial problem facing health and fitness businesses — technological obsolescence — and unveil their solution for it: a groundbreaking leasing program. “This program makes technological obsolescence itself obsolete,” said Daniel Park, InBody’s Vice President of Sales. “Instead of buying a product that will eventually go out of date, you pay for a service that inclu
- Pyramid Labs Appoints Dirk Lange as CEO and Announces a Doubling of Commercial Fill-Finish Capacityon March 6, 2024
COSTA MESA, Calif.--(BUSINESS WIRE)--Pyramid Labs, Inc. (“Pyramid” or the “Company”), a leader in drug product contract development and manufacturing with expertise in proteins, oligos, and peptides, announced today the appointment of Dirk Lange as Chief Executive Officer. Medhat Gorgy, who founded Pyramid in 1988 and has led the Company’s growth and evolution over its 36-year history, will continue to support the business as the Company’s chairman. “I am excited to lead Pyramid during this piv
- STAAR Surgical to Participate in Two Upcoming Investor Conferenceson March 6, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors at the following conferences: Oppenheimer Healthcare MedTech & Services Conference, Tuesday, March 12 Sidoti Small Cap Conference, Wednesday, March 13 Management will also meet with investors in
- N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Studyon March 5, 2024
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV. Published in The Journal of Infectious Diseases, researchers at the University of Minnesota Medical School gave six HIV-positive individuals infusions of healthy NK cells from close relatives, along with N-803 to boost NK ce
- Simulations Plus and the University of Bath Awarded New FDA Granton March 5, 2024
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus with university partners was awarded a new FDA grant to expand and validate PBBM/PBPK modeling solutions for topical products.
- Endologix Appoints Mike Mathias as Chief Commercial Officeron March 5, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately. With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix. Matt T